Sangamo Therapeutics

Editing genomes before it was cool

In a lab in Brisbane, California, just south of San Francisco, scientists are designing proteins the size of a rumor. They are called zinc fingers - small, modular, and precise - and their entire job is to find one specific stretch of DNA in the three billion letters of the human genome and do exactly one thing to it. Silence it. Wake it up. Cut it. Turn its volume down like a thumb on a dial.

This is Sangamo Therapeutics, and it has been doing this since 1995. That date matters. When Sangamo started programming the genome, CRISPR was not yet a word anyone outside a microbiology department had heard. The company spent two decades being the cutting edge of genomic medicine, and then watched a newer, flashier gene-editing tool sprint past it in the headlines. The trade press has a name for the moment: lost in the CRISPR hype.

But here is the thing about zinc fingers that the headlines miss. CRISPR is brilliant at cutting. Sangamo's proteins can do something subtler - they can act as a dimmer switch for a gene, repressing or boosting its expression without ever breaking the DNA strand. For a brain disease where you do not want to start cutting, that distinction is not academic. It is the whole ballgame.

The patient at the center of it

Strip away the platform talk and you arrive at a person with Fabry disease. Fabry is a rare, inherited disorder where a missing enzyme lets fatty material build up in cells, slowly damaging the kidneys, heart, and nervous system. The standard treatment is enzyme replacement therapy - an infusion, every two weeks, for life. It is a tether.

Sangamo's lead candidate, ST-920 (isaralgagene civaparvovec), is a wholly owned gene therapy designed to cut that tether. One infusion. No preconditioning chemotherapy - which is rare and meaningful in this field. The body's own cells are instructed to start producing the missing enzyme, and keep producing it.

The data is why people are paying attention again. In the Phase 1/2 STAAR study, across 23 patients followed at least a year, kidney function trended the right way - a positive mean eGFR slope of roughly 3.06 mL/min/1.73m² per year. And of the 18 patients who walked in on enzyme replacement therapy, all 18 were taken off it and stayed off. In late 2025 Sangamo initiated a rolling Biologics License Application to the FDA under the Accelerated Approval Program, with the full submission targeted for the summer of 2026.

Back to the lab in Brisbane

Return to that Brisbane lab and the proteins the size of a rumor. The work hasn't changed - find the gene, do one precise thing - but the room around it has. What was once a research platform looking for a use is now a company with a therapy in front of the FDA and a list of patients who came off their fortnightly infusions and stayed off.

The honest part: 2026 finds Sangamo a micro-cap underdog, weighing strategic alternatives, raising money in tranches, doing the unglamorous math of keeping a thirty-year experiment alive long enough to finish a BLA. There is no superlative that survives contact with that balance sheet.

But the science kept its promise. The zinc finger - patient, modular, willing to whisper to a single gene instead of shouting at all of them - turned out to be exactly the tool a brain disease wants. The pioneers who got passed in the hype cycle are still, quietly, the ones who can dial a gene up or down on command. The lab in Brisbane is betting the rest of medicine eventually needs that dial. The next few quarters will say whether the bet pays.